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More than 97% of patients diagnosed with small cell lung 
cancer (SCLC) present with very advanced loco-regional 
and often systemic involvement, a group of patients in 
whom surgery has no role to play save the odd case where 
the surgeon may be asked to provide additional tissue to 
confirm the diagnosis. Less than 3% of SCLC patients 
however will be diagnosed at an early stage (N0–N1) and 
the role of surgery in these unusual SCLC patients remains 
underutilized. 
Over the years, many small series, mostly retrospective, 
have shown excellent survival for stage I SCLC patients 
who were treated surgically. Though in many cases these 
individuals had undergone resection without a diagnosis of 
SCLC histology prior to surgery, the fact has repeatedly 
remained that this very small sub-population of SCLC 
patients do very well after good surgery combined with, 
since the late 1970s, adjuvant cisplatin based chemotherapy. 
In many centers however, chemoradiation therapy alone 
remains the only option offered.
In the absence of randomized studies evaluating the best 
local modality to treat these rare early stage tumors, case 
series and small phase II studies have historically guided us 
in their management. Wakeam et al. now provide us with a 
propensity-matched analysis of survival where the strategy 
of surgery and adjuvant chemotherapy was compared 
to that of chemoradiation therapy for the treatment of 
early and locally advanced SCLC (1). The surgical cohort 
identified represented 1.3% of all SCLC registered in the 
US National Cancer Data Base in between 2004 and 2013: 
2,089 surgical patients, 1,310 with clinical stage I, 335 
clinical stage II and 401 with clinical stage III. 
This analysis confirmed nearly a double in median 
overall survival for N0 patients treated with surgery: 38 vs. 
22 months. Their analysis also showed that the benefits of 
surgery were only seen when an R0 resection was achieved, 
that lobectomy was superior to sublobar resections and to 
pneumonectomies and that adjuvant chemotherapy should 
be considered after these R0 resections. These findings had 
all been hinted previously in smaller published series or 
non-randomized prospective trials, the size of the cohorts 
reported here re-enforces these principles.
From my point of view, in 2017, despite the absence 
of phase III randomized trials, it is more than reasonable 
to offer primary resection to these patients as strongly 
suggested by the results of this analysis. These patients 
however should all get invasive mediastinal staging and 
brain imaging upfront. We have reported previously that 
there is a significant discrepancy in between clinical and 
pathological staging in these patients with 20% of clinical 
stage I–II patients being upstaged as well as up to one 
third of clinical stage III patients being downstaged after 
resection (2). 
As suggested by the observations of Wakeam et al., the 
extent of resection should probably be at least a lobectomy, 
though in patients with limited pulmonary reserves for 
which tumor an anatomical segmentectomy is feasible, 
without oncological compromise, such an anatomical limited 
resection may possibly be a good option. The role of surgery 
when a pneumonectomy is required is probably very limited.
Whatever the size of the lesion, even with pN0 disease, 
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adjuvant chemotherapy should be considered standard 
of care for all resected SCLC patients. The role of post-
operative radiation therapy is less well defined and our 
approach has been to offer it sequentially to chemotherapy 
in most patients with resected pN+ disease, any pN+ 
involvement, even when an R0 resection was achieved. 
SCLC is usually associated with a very rapid growth 
rate and early dissemination to regional lymph nodes and 
distant sites. Are these early SCLCs a biologically distinct 
population despite apparent similar histology? There may 
be some merit in pooling our limited banked resected 
SCLC to evaluate their genetic make-up and evaluate 
whether genomics could help us better identify those in 
whom surgery should be considered in the future.
The surgical cohort studied by Wakeam et al. was 
collected in between 2004 and 2013. It is humbling to 
note that the survivals we reported after surgery for SCLC 
collected one decade earlier by the International Association 
for the Study of Lung Cancer (IASLC) Lung Cancer 
Staging Project had very similar survivals of around 55% for 
resected pathological stages I SCLC, 40% for pathological 
stage II and 12% for pathological stage III.
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